|

SLC-3010 + Axitinib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Yonsei University1

Indications

  • Malignant Neoplasm of Kidney, Except Renal Pelvis1
  • Clear Cell Renal Cell Carcinoma1
  • Malignant Neoplasms1
  • Neoplasms1
  • Cancer1

Other1 trial

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.